Literature summary for 2.3.1.32 extracted from

Seo, M.; Song, M.; Seok, Y.M.; Kang, S.H.; Lee, H.A.; Sohn, U.D.; Kim, I.K.
Lysine acetyltransferases cyclic adenosine monophosphate response element-binding binding protein and acetyltransferase p300 attenuate transcriptional activity of the mineralocorticoid receptor through its acetylation (2015), Clin. Exp. Pharmacol. Physiol., 42, 559-566.

Search for more literature for 2.3.1.32

Application

Application	Comment	Organism
pharmacology	cyclic adenosine monophosphate response element-binding binding protein and p300 are lysine acetyltransferases responsible for the regulation of mineralocorticoid receptor providing therapeutic targets for the treatment of hypertension	Homo sapiens

Cloned(Commentary)

Cloned (Comment)	Organism
nuclear enzyme overexpression in HEK-293 cells	Homo sapiens

Protein Variants

Protein Variants	Comment	Organism
additional information	in human embryonic kidney 293 cells, overexpression of cyclic adenosine monophosphate response element-binding binding protein, CBP, or p300, but not p300/CBP-associated factor, increases mineralocorticoid receptor acetylation and decreases expression of mineralocorticoid receptor target genes	Homo sapiens

Localization

Localization	Comment	Organism	GeneOntology No.	Textmining
nucleus	-	Homo sapiens	5634	-

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Synonyms

Synonyms	Comment	Organism
acetyltransferase p300	-	Homo sapiens
Cbp	-	Homo sapiens
cyclic adenosine monophosphate response element-binding binding protein	-	Homo sapiens
lysine acetyltransferase	-	Homo sapiens
p300	-	Homo sapiens

General Information

General Information	Comment	Organism
physiological function	the acetyltransferases cyclic adenosine monophosphate response element-binding binding protein (CBP) and acetyltransferase p300 attenuate transcriptional activity of the mineralocorticoid receptor through its acetylation	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)